Lecanemab for Early Alzheimer's Disease Treatment Options

A blood test just moved Alzheimer's diagnostic accuracy in primary care from 65% to 93%. That finding, presented at AAIC last week, is the biggest thing to happen to dementia diagnostics in years. Real-world study, 1,300+ patients, 165 physicians. GPs went from guessing to near-specialist performance. Roughly a third of patients had their diagnosis changed once the result came back. Here's the part I can't stop thinking about. A blood test answers "does this person have Alzheimer's pathology?" It does not answer "which of the 2,000 patients on my list should I draw blood from?" We just solved confirmation. We did not solve triage. Triage is where the bottleneck actually sits - especially across Asia-Pacific, where specialist density is low, memory clinic waitlists are long, and cognitive decline is usually first noticed by a family member rather than a clinician. You can't draw blood from an entire ageing population on suspicion. That gap is why we build what we build at Unicorn Labs: speech-based screening designed to tell a clinician who to send for the confirmatory test, not to replace it. A few minutes of voice, analysed for the speech biomarkers that shift long before anyone books an appointment. The better confirmatory testing gets, the more valuable cheap, scalable, non-invasive triage becomes. Blood-based and digital biomarkers aren't competitors. They're two ends of the same funnel. For those of you in primary care or health system planning: what's your realistic path from "we now have an accurate blood test" to "we know who to test"? Source in the comments.

This is worth examining - a double-blind, placebo controlled trial in Alzheimer's patients showed a THC:CBD combo med significantly reduced agitation. A combination of CBD and THC rapidly and significantly reduces agitation in hospice eligible people with dementia, suggest topline results from the Phase 2 LiBBY (Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol) clinical trial. The findings were reported for the first time at the Alzheimer’s Association International Conference® (AAIC®) 2026 in London and online. “This is a robustly positive, randomized, controlled trial that represents a major step forward in treatment for a population that has been historically overlooked in clinical research,” said lead investigator Jacobo Mintzer. M.D., Psychiatrist at the Ralph H. Johnson VA Healthcare System, and Professor, College of Health Professions, Medical University of South Carolina. “We now have evidence supporting a new and very effective treatment approach for agitation that may be appropriate for people in the final stages of dementia at the end of life, offering them grace and peace in what is often an extremely difficult time for patients and their families.” The multicenter, randomized, double-blind, placebo-controlled study evaluated a novel oral formulation (2 mg THC/100 mg CBD dissolved in digestible oil, provided twice a day) in 120 participants with dementia who were eligible or received hospice care and experiencing clinically significant agitation. The trial achieved its primary and key secondary endpoints.

🚨BREAKING: Scientists Just Discovered What's Really Causing POTS For years, dysautonomia patients were told their condition was "all in their head." That narrative just changed. Over 400 clinicians and researchers at the 14th annual Dysautonomia International conference just unveiled findings that will reshape how we understand and treat POTS. Here's what they found: 🔬 80% of POTS patients have platelet dysfunction linked to chronic inflammation 🧬 Researchers identified specific autoantibodies that could revolutionize diagnosis 🏥 A new biobank called POTS BRAIN is accelerating research by collecting blood samples and medical histories ⚡ Dysautonomia is officially recognized as an inflammatory and autoimmune condition—not a psychological issue But here's what caught my attention most: The conference emphasized the critical importance of recognizing post-exertional malaise in patients with both POTS and ME. This matters because it validates what thousands of patients have been saying for years. When you push through symptoms, you don't get better—you crash harder. The science now backs this up. This breakthrough opens doors to: ✅ Better diagnostic tools ✅ Targeted treatments based on biomarkers ✅ Faster identification of at-risk patients ✅ Validation for patients who've been dismissed For the dysautonomia community, this is a turning point. For researchers, it's a roadmap. For patients who've been gaslit about their condition—it's vindication. Read the full breakdown here: https://lnkd.in/ec7pXYvy What aspect of this research excites you most? Drop your thoughts below. 👇

Reaching 50 patients in our DETECT study ahead of schedule is a significant milestone for Epiminder and one I am very pleased to share. The milestone was achieved ahead of our previously stated mid-Q3 CY2026 target and follows the 25th enrolment announced on 1 June. DETECT is Epiminder’s US study evaluating the FDA-authorised Minder® System in patients whose prolonged EEG monitoring was inconclusive. Key highlights: • 50 patients now enrolled in DETECT • 20 leading US clinical sites actively recruiting, including Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania • Enrolment remains on track to reach 210 patients by the end of 1H CY2027 We are seeing growing engagement across the DETECT network. The pace of recruitment and calibre of participating centres indicate increasing clinician confidence in Minder and its potential to address a significant diagnostic gap in drug-resistant epilepsy. Each enrolment represents a patient who has not received a conclusive answer through conventional monitoring. DETECT is building the evidence needed to show how long-term monitoring during daily life may support better clinical decisions and improved patient care. Read the full announcement: https://lnkd.in/gjj8hdWB

Innovation in nephrology continues to reshape patient care. The recent U.S. FDA accelerated approval of TRUTAKNA™ (atacicept) for adults with primary IgA nephropathy (IgAN) is a notable milestone. As the first FDA-approved therapy targeting both BAFF and APRIL, it represents a novel approach to addressing the underlying immune mechanisms of this progressive kidney disease. Backed by positive Phase 3 clinical data, this approval highlights how scientific innovation continues to expand treatment possibilities for patients with unmet medical needs. Every new approval is a reminder of the impact that research, collaboration, and evidence-based innovation can have on improving lives.

Blood-based biomarkers could dramatically widen access to early Alzheimer's diagnosis: they're low-cost and scalable across a wide variety of care settings. Whether that promise shows up for patients and families depends entirely on health system readiness. That's the exact question Milken Institute just put out a report on: "Advancing Blood-Based Biomarkers for Alzheimer's and Cognitive Care." They interviewed 32 people across health systems, payers, guideline bodies, patient advocacy, and diagnostics companies, and scored the field on five things that actually determine whether BBMs get deployed: clinical guidelines, diagnostic positioning, evidence for coverage, payer policy, and equity of access. Good to see it draw on people who've actually figured out how to make these tests work in the real world. Davos Alzheimer's Collaborative's Amy Deckert, PhD and I were part of the interviews, and the report features work happening at Atrium Health Wake Forest Baptist, Indiana University Health, University of Kansas Medical Center, and Emory Healthcare - real primary care sites already using blood-based biomarkers, working out referral pathways and staffing models as they go. Nice work by Michael T. Brown, MBA and Diane Ty at Milken Institute putting this together. Worth a read! https://lnkd.in/g3GrAvtu

🧠 Treating Alzheimer's Before It's Too Late What if Alzheimer's disease begins long before the first memory is lost? Learning about Lecanemab changed the way I think about dementia pharmacology. Unlike traditional treatments that mainly help manage symptoms, Lecanemab targets beta amyloid, one of the proteins involved in Alzheimer's disease, with the goal of slowing its progression in carefully selected patients. What I found most interesting wasn't just how the drug works. It was the shift in thinking it represents. Instead of asking, "How do we treat dementia?" we're beginning to ask, "How do we identify and intervene before irreversible brain damage occurs?" While Lecanemab is a remarkable scientific advance, challenges such as ARIA, the need for MRI monitoring, high treatment costs, and limited accessibility remind us that innovation is only meaningful when patients can safely benefit from it. One lesson stood out to me: The future of Alzheimer's care may depend just as much on earlier diagnosis as it does on better medicines. As a pharmacy student, this reflection reminded me that great pharmacology isn't only about discovering new drugs. It's about changing the future of patient care. What are your thoughts? Will earlier diagnosis or better therapies have the biggest impact on Alzheimer's care in the years ahead? #Pharmacology #AlzheimersDisease #Lecanemab #Dementia #DrugInnovation #FuturePharmacist #Healthcare Ermias M. Terefe, PhD. United States International University - Africa. Pharmacy and Poisons Board. Ministry of Health, Kenya. World Health Organization

THC and CBD reduce agitation in patients with advanced dementia, clinical study shows. Clinical study points to symptom improvement in patients, while specialists reinforce the need for caution and more evidence. https://lnkd.in/gtVdKtDG 

A systematic review and meta-analysis published in BMC Complementary Medicine and Therapies on November 9, 2020 reviewed four randomized clinical trials involving 203 participants and found that 30 mg of standardized saffron extract daily significantly improved memory, thinking, learning, attention, and overall cognitive function in people with mild to moderate Alzheimer's disease compared with placebo, while showing effects comparable to standard Alzheimer's medications such as donepezil and memantine. The review also reported a trend toward better daily functioning, found no serious adverse effects, and concluded that saffron may be a safe and promising natural option for supporting cognitive health, although larger, high-quality clinical trials are still needed to confirm these benefits.

Happy World Brain Day!! Blood-based biomarkers are moving Alzheimer’s diagnosis into a new era. A July 2026 Milken Institute report https://lnkd.in/eZeR8faE Five important takeaways: 1.  Blood tests are changing Alzheimer’s diagnosis. 2.  Clinical readiness is ahead of insurance coverage. 3.  Primary care can be the front door. 4.  An accurate diagnosis has value beyond treatment eligibility. 5.  We should build clinical workflows now. The next generation of biomarkers is already emerging. Health systems that establish processes for ordering, interpreting, and counseling patients today will be better prepared for tomorrow. The message is clear: blood-based biomarkers can expand access to earlier Alzheimer’s diagnosis—but education, equitable coverage, and coordinated clinical pathways must keep pace.